De Novo Membrano-Proliferative Nephritis Following Interferon Therapy for Chronic Hepatitis C (Case Study and Literature Review)
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
HCV infects approximately 2–3 % of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Antiviral treatment with pegylated interferon and ribavirin eradicates HCV in many patients, while 40–90 % of patients on pegylated IFN plus ribavirin have sustained viral clearance . However, IFN-based therapy is limited by frequent and, at times, serious adverse effects which represent an important barrier to treatment delivery. In clinical trials, approximately 10–15 % of patients discontinue peg-IFN and ribavirin therapy due to adverse effects, but, in clinical practice, the rate of treatment interruption is probably higher. Combined antiviral therapy (conventional or pegylated IFN plus ribavirin) impacts most, if not all, organ systems. According to the KULDS Group, the rate of treatment discontinuation was 8.7 % (n = 250) in a total of 2,871 Japanese patients who had chronic HCV treated with peg-IFN α-2b and RBV ....
- Ogawa E, Furusyo N, Kajiwara E, et al. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from the Kyushu University Liver Disease Study [KULDS] Group. J Gastroenterol Hepatol. 2012;27:1233–1240. CrossRef
- Johnson R, Gretch D, Couser W, et al. Hepatitis C virus-associated glomerulonephritis. Effects of α-interferon therapy. Kidney Int. 1994;46:1700–1704. CrossRef
- Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int. 2008; 73: S1–S99.
- Cattran D. Interferon therapy: a double-edged sword? Am J Kidney Dis. 1999;33:1174–1176. CrossRef
- Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26:S112–S121. CrossRef
- Ohta S, Yokoyama H, Wada T, et al. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis. 1999;33:1040–1048. CrossRef
- Roithinger F, Allinger S, Kirchgatterer A, et al. A lethal course of chronic hepatitis C, glomerulonephritis, and pulmonary vasculitis unresponsive to interferon treatment. Am J Gastroenterol. 1995;90:1006–1009.
- Coroneos E, Petrusevska G, Varghese F, Truong L. Focal segmental glomerulosclerosis with acute renal failure associated with α-interferon therapy. Am J Kidney Dis. 1996;28:888–892. CrossRef
- Horino T, Kuriyama S, Tomonari H, et al. Renal damage in a chronic active hepatitis C patient receiving interferon-alpha therapy. Nihon Jinzo Gakkai Shi. 1998;40:48–53.
- Endo M, Ohi H, Fujita T, Ohsawa I, Kanmatsuse K, Yamaguchi Y. Appearance of nephrotic syndrome following interferon-α therapy in a patients with hepatitis B virus and hepatitis C virus coinfection. Am J Nephrol. 1998;18:439–443. CrossRef
- Stein D, Ahmed A, Sunkhara V, Khalbuss W. Collapsing focal segmental glomerulosclerosis with recovery of renal function: an uncommon complication of interferon therapy for hepatitis C. Dig Dis Sci. 2001;46:530–535. CrossRef
- Nishimura S, Miura H, Yamada H, Shinoda T, Kitamura S, Miura Y. Acute onset of nephrotic syndrome during interferon-α treatment for chronic active hepatitis C. J Gastroenterol. 2002;37:854–858. CrossRef
- Willson R. Nephrotoxicity of interferon alpha-ribavirin therapy for chronic hepatitis C. J Clin Gastroenterol. 2002;35:89–92. CrossRef
- Dizer U, Beker C, Yavuz I, Ortatatli M, Ozguven V, Pahsa A. Minimal change disease in a patient receiving IFN-α therapy for chronic hepatitis C virus infection. J Interferon Cytokine Res. 2003;23:51–54. CrossRef
- Suresh R, Suryati Y, Merican I. Interferon induced glomerular disease in a patient with chronic hepatitis C. Med J Malays. 2003;58:594–596.
- Fisher M, Rossini M, Simmons E, Harris R, Moeckel G, Zent R. A woman with chronic hepatitis C infection and nephrotic syndrome who developed multiple renal lesions after interferon alpha therapy. Am J Kidney Dis. 2004;44:567–573. CrossRef
- Gordon A, Menahem S, Mitchell J, Jenkins P, Dowlings J, Roberts S. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy. Nephrol Dial Transpl. 2004;19:2155–2159. CrossRef
- Couto A, Faria L, Ribeiro D, de Paula F, de Melo Couto O, de Abreu Ferrari T. Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon alpha-2b and ribavirin treatment for hepatitis C. Liver Int. 2006;26:1294–1297. CrossRef
- Tovar J, Buti M, Segarra A, Majò J, Esteban R. De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection. Int Urol Nephrol. 2008;40:539–541. CrossRef
- Kanungo S, Tamirisa S, Gopalakrishnan R, Salinas-Madrigal L, Bastani B. Collapsing glomerulopathy as a complication of interferon therapy for hepatitis C infection. Int Urol Nephrol. 2010;42:219–222. CrossRef
- Markowitz G, Nasr S, Stokes M, D’Agati V. Treatment with IFN-α, -β or -γ is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5:607–615. CrossRef
- Tsai M, Chen J, Fang Y, Yang A, Chang C. Membranous nephropathy induced by pegylated interferon α-2a therapy for chronic viral hepatitis B. Clin Nephrol. 2012;77:496–500. CrossRef
- Lai K, Wei C, Tan L, et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol. 2007;18:1476–1485. CrossRef
- Gresser I. Interferon: an unfolding tale. J Interferon Cytokine Res. 2007;27:447–452. CrossRef
- Kimmel P, Abraham A, Phillips T. Membranoproliferative glomerulonephritis in a patient treated with interferon-α for human immunodeficiency virus infection. Am J Kidney Dis. 1994;24:858–863.
- Yokoyama H, Takaeda M, Wada T, et al. Intraglomerular expression of MHC-class II and Ki-67 antigens and serum γ-interferon levels in IgA nephropathy. Nephron. 1992;62:169–175. CrossRef
- De Novo Membrano-Proliferative Nephritis Following Interferon Therapy for Chronic Hepatitis C (Case Study and Literature Review)
Digestive Diseases and Sciences
Volume 59, Issue 3 , pp 691-695
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Hepatitis C
- Membrano-proliferative glomerulonephritis
- Industry Sectors
- Author Affiliations
- 1. Division of Nephrology, Maggiore Hospital, IRCCS Foundation, Pad. Croff, Via Commenda 15, 20122, Milan, Italy
- 2. Division of Digestive Diseases, Maggiore Hospital, IRCCS Foundation, Milan, Italy
- 3. Division of Hepatology, School of Medicine, University of Miami, Coral Gables, FL, USA